Regardless of tumor burden, outcomes after liver transplantation are superior to resection for patients with cHCC-CCA. For cHCC-CCA within Milan, liver transplant was associated with improved disease-free survival over resection (70.3% vs 33.6% 5 years, p < 0.001). Irrespective of tumor burden, cHCC-CCA tumor patient undergoing liver transplant had significantly superior overall survival (p = 0.047) and disease-free survival (p < 0.001) than those having resection. Liver transplantation for cHCC-CCA (n = 67) and HCC (n = 1,814) within Milan had no significant difference in overall survival (5-year cHCC-CCA 70.1%, HCC 73.4%, p = 0.806), despite higher cHCC-CCA recurrence rates (23.1% vs 11.5% 5 years, p < 0.001).

Cox regression was used for multivariate survival analysis. Kaplan-Meier survival curves and log-rank test were used to determine overall survival and disease-free survival.

Tumor burden was based on radiologic Milan criteria at time of diagnosis and applied to cHCC-CCA for uniform analysis. Liver transplant and resection outcomes for HCC (n = 2,998) and cHCC-CCA (n = 208) were compared in a 12-center retrospective review (2009 to 2017). Through a multicenter collaboration, we performed the largest analysis to date of the utility of liver transplantation for cHCC-CCA. Published results are from small cohorts and single centers. *Correspondence address: Leigh Anne Dageforde, MD, MPH, FACS, Massachusetts General Hospital, Department of Surgery, Division of Transplantation, 55 Fruit St, White 511, Boston, MA 02114.Ĭombined hepatocellular-cholangiocarcinoma liver tumors (cHCC-CCA) with pathologic differentiation of both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma within the same tumor are not traditionally considered for liver transplantation due to perceived poor outcomes. Selected for the 2020 Southern Surgical Association Program. Dr Doyle was a member of the Novartis Scientific Advisory Board. Received NovemAccepted November 30, 2020.ĭisclosure Information: Nothing to disclose.ĭisclosures outside the scope of this work: Dr Chapman is a member of the Novartis Scientific Advisory Board, serves on the Board of Directors for Mid-America Transplant, and receives payment for intellectual property from Pathfinder Therapeutics. PCedars-Sinai Medical Center, Los Angeles, CA OBeth Israel Deaconess Medical Center, Boston, MA NColumbia University Irving Medical Center, New York, NY MUniversity of California San Diego, San Diego, CA KMemorial Sloan Kettering Cancer Center, New York, NY IMedical College of Wisconsin, Milwaukee, WI MD, MBA, FACS bĪMassachusetts General Hospital, Boston, MAīWashington University in St Louis, Saint Louis, MOĬIcahn School of Medicine at Mount Sinai, New York, NYĭUCLA School of Medicine, Los Angeles, CAįOregon Health and Science University, Portland, OR

MD, PhD a Yang, Ju Dong MD p Kim, Joohyun MD, PhD q Pasko, Jennifer MD r Chapman, William C. MD c Srouji, Rami MD b Najjar, Marc MD, MS n Yohanathan, Lavanya MD h Cheng, Jane MD o Amin, Hiral BS j Rickert, Charles A. MD, FACS i Lee, David MD, FACS i Ferrone, Cristina MD, FACS a Baker, Erin MD, FACS j Jarnagin, William MD, FACS k Hemming, Alan MD, FACS l Schnickel, Gabriel MD, MPH, FACS m Kimura, Shoko MD, FACS l Busuttil, Ronald MD, PhD, FACS d Lindemann, Jessica MD b Florman, Sander MD, FACS c Holzner, Matthew L. Southern surgical association article Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumorsĭageforde, Leigh Anne MD, MPH, FACS a,* Vachharajani, Neeta BS b Tabrizian, Parissa MD, MSc, FACS c Agopian, Vatche MD, FACS d Halazun, Karim MD, MPH, FACS e Maynard, Erin MD, FACS f Croome, Kristopher MD, FACS g Nagorney, David MD, FACS h Hong, Johnny C.

Ucsf graphpad prism